In August, Hangzhou Municipal Science and Technology Bureau accredited Westlake Omics in the list of High-tech Research and Development Centers in 2022, signifying the inauguration of the Proteomics R&D Center of the quasi-unicorn company.
As a micro-world data company empowered by AI, Westlake Omics is driven by proteomic big data technological innovation to promote precision medicine and drug development.
The company currently focuses on the indeterminate thyroid nodule diagnostic products, with other pipelines advanced in different stages. The multidisciplinary team of AI plus multi-omics is innovatively applying proteomics in multiple aspects of disease diagnosis and drug development.
In August, Hangzhou Municipal Science and Technology Bureau accredited Westlake Omics in the list of High-tech Research and Development Centers in 2022, signifying the inauguration of the Proteomics R&D Center of the quasi-unicorn company.
As a micro-world data company empowered by AI, Westlake Omics is driven by proteomic big data technological innovation to promote precision medicine and drug development.
The company currently focuses on the indeterminate thyroid nodule diagnostic products, with other pipelines advanced in different stages. The multidisciplinary team of AI plus multi-omics is innovatively applying proteomics in multiple aspects of disease diagnosis and drug development.
